Organization

Zuckerberg Cancer Center, Northwell Health Cancer Institute

1 abstract

Abstract
A phase 1 study of fianlimab (anti–LAG-3) in combination with cemiplimab (anti–PD-1) in patients with advanced HNSCC.
Org: Zuckerberg Cancer Center, Northwell Health Cancer Institute, Tallaght University Hospital,